Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost and expenses: | ||||
| Cost of sales (excluding amortization of in-licensed rights) | 149,385 | 152,558 | 258,153 | 290,122 |
| Research and development | 91,258 | 204,392 | 245,218 | 977,840 |
| Selling, general and administrative | 107,600 | 137,897 | 216,551 | 271,526 |
| Litigation contingency charge | 39,000 | — | 39,000 | — |
| Amortization of in-licensed rights | 717 | 667 | 1,408 | 1,268 |
| Total cost and expenses | 387,960 | 495,514 | 760,330 | 1,540,756 |
| Operating income (loss) | 13,291 | 115,577 | 371,724 | (184,809) |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s SG&A?
- Sarepta Therapeutics, Inc. (SRPT) reported SG&A of $107.6M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s SG&A changed year-over-year?
- Sarepta Therapeutics, Inc.'s SG&A decreased by 22.0% year-over-year, from $137.9M to $107.6M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Sarepta Therapeutics, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude